Gibbs v. EI DuPont De Nemours & Co., Inc.

876 F. Supp. 475, 25 Envtl. L. Rep. (Envtl. Law Inst.) 20926, 1995 U.S. Dist. LEXIS 1623, 1995 WL 60788
CourtDistrict Court, W.D. New York
DecidedFebruary 6, 1995
Docket1:93-cv-00497
StatusPublished
Cited by24 cases

This text of 876 F. Supp. 475 (Gibbs v. EI DuPont De Nemours & Co., Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gibbs v. EI DuPont De Nemours & Co., Inc., 876 F. Supp. 475, 25 Envtl. L. Rep. (Envtl. Law Inst.) 20926, 1995 U.S. Dist. LEXIS 1623, 1995 WL 60788 (W.D.N.Y. 1995).

Opinion

DECISION and ORDER

CURTIN, District Judge.

BACKGROUND

This is one of a series of cases involving the high incidénce of bladder cancer among employees of the Goodyear Tire & Rubber Company in Niagara Falls, New York. In this action, plaintiffs Harry Gibbs, Robert Bailey, Anthony D’Orazio, and William Mooney, all former employees of Goodyear, sue defendants DuPont, Allied-Signal, First Mississippi, First Chemical, Cyanamid and USX in negligence and strict product liability. Plaintiffs claim that the defendants manufactured and sold orthotoluidine and/or anilide to Goodyear without providing adequate warning of the health hazards of these products. Plaintiffs further claim that these chemical compounds were defective and unreasonably dangerous when used in a foreseeable manner and that exposure to these substances subjected them to a significant excess risk of developing bladder cancer.

Plaintiffs move to certify a class under Rule 23(b)(2) of the Federal Rules of Civil Procedure of all retired and former Goodyear employees at the Niagara Falls plant who were assigned to work in Department 245 or *477 had job duties which exposed them to the substances orthotoluidine and aniline during the period of January 1, 1957, through June 11, 1990, and who have not been diagnosed with bladder cancer. None of the named plaintiffs claim to have any present physical injury. Rather, they rely on a study conducted by the National Institute for Occupational Safety and Heath (“NIOSH”), which found that the Goodyear workers at the Niagara Falls plant have an excess risk of developing bladder cancer ranging from 3.6 to 27.2 times the normal risk. Because of the long latency period, NIOSH recommended an ongoing medical monitoring program designed to detect bladder cancer at its earliest stage. 1 Thus, plaintiffs seek injunc-tive relief in the form of a court-administered fund paid for by defendants which would cover the reasonably anticipated costs of a medical monitoring program for bladder cancer for the lifetime of the class members.

Defendants move to dismiss the complaint on several grounds. They assert that plaintiffs’ claim is moot because Goodyear already provides a medical monitoring program and the plaintiffs’ union, the Oil, • Chemical, and Atomic Workers, provides bladder cancer screening. They argue that plaintiffs have failed to state a claim because New York State law does not recognize a cause of action for medical monitoring damages. They contend that the court has no subject matter jurisdiction because plaintiffs’ individual claims do not exceed $50,000, the statutory minimum amount in controversy for diversity-jurisdiction. Finally, defendants oppose the motion for class certification on the grounds that: 1) plaintiffs failed to conform to Local Rule 15, thereby waiving their class allegations; 2) plaintiffs’ pleadings do not satisfy the threshold requirements of Rule 23(a); and 3) class certification for injunctive relief is inappropriate for a medical monitoring claim.

DISCUSSION

I. Mootness

Federal courts must determine whether there is a live controversy before assuming jurisdiction. Mathis v. Bess, 692 F.Supp. 248, 257 (S.D.N.Y.1988). Defendants argue that plaintiffs’ claims are moot because Goodyear has a medical monitoring program that screens current and former employees for bladder cancer which is comprehensive and uses all medically appropriate tests and technology. See Item 30, Exhibit N (Hense Aff.).

Plaintiffs reply that the screening program is inadequate because: (1) it is not available to former employees who are not retirees; (2) certain necessary tests are not offered to those who reside outside Western New York; (3) the program is only experimental; (4) participants may not enter the program until their birth month, (5) follow-up procedures are below the expected standard of care, (6) it fails to provide for technological advances, outreach, education, and data analysis and dissemination, and (7) the Goodyear health insurance plan for retirees, providing a collateral source for follow-up tests, gives no relief for other former employees. Item 31 at 13-14, Ex. E (Aliotta Aff.). In a supplemental memorandum, the plaintiffs further contend that even if the current program was adequate, defendants'have failed to show that the plaintiffs have any legal entitlement to its continuation. Item 38.

The issue of whether the medical monitoring currently available to named plaintiffs and those in the proposed class is adequate is necessarily one of fact. Both parties have submitted expert affidavits concerning the types of procedures which are necessary to insure early detection of bladder cancer. Plaintiffs have provided a sufficient critique of the current Goodyear program to show that a factual dispute' exists' regarding its adequacy. Therefore, summary judgment on mootness is inappropriate at this stage.'

II. Medical Monitoring

Defendants contend that plaintiffs’ complaint fails to state a claim because the New York Court of Appeals has not and, if presented with the issue, would not recognize a cause of action for medical monitoring. *478 State law announced by the highest court in the forum state is controlling in federal court in a diversity case. Erie Railroad v. Tompkins, 304 U.S. 64, 68 S.Ct. 817, 82 L.Ed. 1188 (1938). Where there is no decision by the highest court, “then federal authorities must apply what they find to be the state law after giving ‘proper regard’ to relevant rulings of other courts of the state.” Commissioner v. Bosch, 387 U.S. 456, 465, 87 S.Ct. 1776, 1782, 18 L.Ed.2d 886 (1967). The New York Court of Appeals has not yet recognized a cause of action for medical monitoring. Defendants cite several examples of Court of Appeals decisions which express hesitancy at the judicial creation or expansion of tort liability in such fields as psychic injury, DES, fetal rights, and asbestos. Item 21 at 28-32. They argue that this caution by New York’s highest court would carry over to medical monitoring. Defendants urge this court not to create such an expansion in the absence of any clear direction from the state judiciary.

Plaintiffs claim to the contrary that New York was one of the first states to recognize that the future expenses of medical monitoring could be a recoverable consequential damage from exposure to toxic chemicals if the plaintiffs could prove an increased risk of future harm by reason of their exposure and a reasonable anticipation that the expenditures for medical monitoring would be incurred as a result. Askey v. Occidental, 102 A.D.2d 130, 477 N.Y.S.2d 242, 247 (4th Dept. 1984). Plaintiffs cite several earlier cases to show that Askey is consistent with well-settled New York law. See Item 31 at 29-30.

Defendants counter that the discussion plaintiffs rely on in Askey

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Baker v. Saint-Gobain Performance Plastics Corp.
232 F. Supp. 3d 233 (N.D. New York, 2017)
Caronia v. Philip Morris USA, Inc.
5 N.E.3d 11 (New York Court of Appeals, 2013)
Caronia v. Philip Morris USA, Inc.
715 F.3d 417 (Second Circuit, 2013)
Donovan v. Philip Morris USA, Inc.
268 F.R.D. 1 (D. Massachusetts, 2010)
Gates v. Rohm & Haas Co.
265 F.R.D. 208 (E.D. Pennsylvania, 2010)
Abbatiello v. Monsanto Co.
522 F. Supp. 2d 524 (S.D. New York, 2007)
In re Welding Fume Products Liability Litigation
245 F.R.D. 279 (N.D. Ohio, 2007)
Mehl v. Canadian Pacific Railway, Ltd.
227 F.R.D. 505 (D. North Dakota, 2005)
State ex rel. McCaffery v. Hutchison
585 S.E.2d 52 (West Virginia Supreme Court, 2003)
In Re West Virginia Rezulin Litigation
585 S.E.2d 52 (West Virginia Supreme Court, 2003)
Bolanos v. Norwegian Cruise Lines Ltd.
212 F.R.D. 144 (S.D. New York, 2002)
Goasdone v. American Cyanamid Corp.
808 A.2d 159 (New Jersey Superior Court App Division, 2002)
In Re Rezulin Products Liability Litigation
168 F. Supp. 2d 136 (S.D. New York, 2001)
Barnes v. Amer Tobacco Co
Third Circuit, 1998
Barnes v. American Tobacco Co.
161 F.3d 127 (Third Circuit, 1998)
William Barnes v. The American Tobacco Company
161 F.3d 127 (Third Circuit, 1998)
Cook v. Rockwell International Corp.
181 F.R.D. 473 (D. Colorado, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
876 F. Supp. 475, 25 Envtl. L. Rep. (Envtl. Law Inst.) 20926, 1995 U.S. Dist. LEXIS 1623, 1995 WL 60788, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gibbs-v-ei-dupont-de-nemours-co-inc-nywd-1995.